AbbVie's strategic acquisition of Aliada Therapeutics for $1.4 billion is a significant move into Alzheimer's innovation. The acquisition enhances AbbVie's R&D capabilities with cutting-edge technology targeting amyloid plaques, strengthening its position in the neuroscience field amidst growing demand for CNS treatments.